Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3041658 (SC), Eltrekibart
LY3041658 · 4 trials · 5 indications
The HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule count (sum of abscesses and inflammatory nodules \[AN count\]) with no increase in abscess count (A count) and no increase in draining fistulae count (DF count) relative to baseline. Non-responder imputation (NRI): Participants with missing data were considered non-responders.
| Arm | Type | Description |
|---|---|---|
| Eltrekibart + Placebo | EXPERIMENTAL | Participants will receive eltrekibart with placebo, eltrekibart or mirikizumab. |
| Mirikizumab + Placebo | EXPERIMENTAL | Participants will receive mirikizumab and placebo or mirikizumab. |
| Eltrekibart + Mirikizumab | EXPERIMENTAL | Participants will receive eltrekibart and mirikizumab in combination or separately as monotherapy. |
| Placebo | EXPERIMENTAL | Participants will receive placebo or mirikizumab. |
| Eltrekibart Dose 1 | EXPERIMENTAL | Eltrekibart will be given subcutaneously (SC). |
| Eltrekibart Dose 2 | EXPERIMENTAL | Eltrekibart will be given SC. |
| Eltrekibart Dose 3 | EXPERIMENTAL | Eltrekibart will be given SC. |
| LY3041658 | EXPERIMENTAL | Participants received 600 mg LY3041658 administered intravenously (IV) once every 2 weeks (Q2W). |
| Name | Type | Description |
|---|---|---|
| Eltrekibart | DRUG | Administered |
| Mirikizumab | DRUG | Administered |
| Placebo | DRUG | Administered |
| LY3041658 | DRUG | Administered IV |
Inclusion Criteria: * Have had an established diagnosis of UC of ≥3 months in duration before baseline. * Have moderately to severely active UC as assessed by the UC disease activity score. * Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib, Lutikizumab |
| Incyte Corporation | INCY | 6 | PHASE3 | povorcitinib, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Remibrutinib, Secukinumab |
| Sanofi SA Sponsored ADR | SNY | 3 | PHASE2 | Duvakitug, Brivekimig, SAR445399 |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Olatorepatide |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY072 |
| Oruka Therapeutics, Inc. | ORKA | 1 | PHASE2 | ORKA-002 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE1 | SAR447971 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE1 | Soquelitinib |
LY3041658 is being studied for hidradenitis suppurativa, a chronic inflammatory skin condition, and more broadly for skin diseases. Eli Lilly and Company has evaluated it in adults with hidradenitis suppurativa and in participants with skin diseases including psoriasis. It remains an investigational therapy rather than an approved treatment.
LY3041658 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating the drug in hidradenitis suppurativa and other skin conditions.
LY3041658 has completed a Phase 2 trial in hidradenitis suppurativa and a Phase 1 trial in skin diseases. No active trials are currently listed, and the drug is investigational, meaning it has not been approved for any indication.
LY3041658 has been evaluated in two completed studies. NCT04493502 was a Phase 2 trial in 72 adults with hidradenitis suppurativa conducted in the United States and Australia. NCT02896868 was a Phase 1 trial in 60 participants with skin diseases, including psoriasis, run in the United States.
The Phase 2 hidradenitis suppurativa study, NCT04493502, was randomized, double blind, and placebo controlled, enrolling 72 adults aged 18 and older of any sex. It completed enrollment across sites in the United States and Australia and did not use biomarker-based patient selection.
Yes, LY3041658 is also referred to as LY3041658 (SC), where SC denotes subcutaneous administration. Both names refer to the same investigational Eli Lilly small molecule being studied in hidradenitis suppurativa and other skin diseases.